Table I.

Patients' Characteristics

Patient	HIV RNAa	CD4 countb	HLA-DRB1	HAARTc	Treatmentd
Group 1
12C	<50	677	*0901, *11	48	DdI, D4T EFV
12B	<50	667	*0101, *07	60	D4T, 3TC, RIT
11C	<50	1,037	*0101, *08	48	EFV (DMP 266-06), IND
13C	<50	461	*0401, *11	48	D4T, 3TC, IND
10C	<50	789	*11, *15	12	RIT, IND, Comb (AZT/3TC)
09B	<50	400	*0401, *1501	13	D4T, 3TC, NFV
02B	<50	604	ND	14	3TC, VER, NFV, D4T
03C	<50	1,064	*0401, *07	12	3TC, AZT, ABC
11B	<50	574	*13, *15	12	Comb (AZT/3TC), NFV
07B	<50	443	*07, *15	12	D4T, 3TC, RIT
Group 2
111	45,000	420	*13, *13	72	AZT, 3TC
112	30,000	529	*03, *04	60	AZT, 3TC
113	65,000	606	*11, *15	24	D4T, 3TC, IND
114	40,000	406	*0103, *07	60	D4T, 3TC, IND
115	10,000	771	*07, *11	60	3TC, AZT, EFV
116	33,452	420	*14, *14	48	3TC, AZT, EFV
117	65,007	344	*04, *13	48	ND
118	73,902	386	ND	72	3TC, AZT, ABC

Group 1, patients with therapy success and no viral rebounds; Group 2, patients with therapy failure due to several viral rebounds throughout therapy.

^aCopies of HIV-1 RNA/ml of plasma at the time of study.

^bPeripheral CD4⁺ T lymphocyte count at the time of study.

^cDuration of current regimen (months).

^dAntiretroviral drug abbreviations: ABC, abacavir; AZT, zidovudine; D4T, savudine; EFV, efavirenz; IND, indinavir; NFV, nelfinavir; 3TC, lamivudine.